Summary by Futu AI
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.